Bone Marrow & Stem Cell Transplant

Lori Muffly, MD, discusses findings a sub-analysis of a phase 1 study investigating briquilimab with low-dose total body radiation and fludarabine.

In an interview with Targeted Oncology, Soyoung Park, MD, discusses the criteria used for determining transplant eligibility and choosing between the different types of transplants for patients with cancer.

Samer A. Srour, MD, discusses research on Orca-Q for patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.

Salman Fazal, MD, discusses the use cases for older matched sibling donors vs younger unrelated donors in stem cell transplants for patients with cancer.

In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.

In an interview with Targeted Oncology, Mitchell E. Horwitz, MD, discussed the FDA approval of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

Nelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.

A GVHD expert outlines the treatments available for patients with chronic GVHD and steroid-refractory chronic GVHD.

Nelson J. Chao, MD, gives an overview of acute and chronic GVHD, and details the classical presentation and staging process.

An expert on graft-vs-host disease discusses allogeneic stem cell transplantation, and reviews transplant conditioning and GVHD prophylaxis regimens.

Nelson J. Chao, MD, presents a patient profile of a 35-year-old woman diagnosed with chronic graft-vs-host disease, and provides his initial thoughts.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed relapse after transplant for patients with cancer and what is important to note moving forward with research.

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Closing out his discussion on chronic graft-vs-host disease, Yi-Bin Chen, MD, looks to the future of GVHD treatment.

Yi-Bin-Chen, MD, discusses the effect of GVHD recurrence and multiple-organ involvement on treatment decisions.

A summary of the systemic treatment options available for steroid-refractory chronic GVHD.

A comprehensive overview of the various treatment options for chronic graft-vs-host disease.

Yi-Bin Chen, MD, describes acute and chronic GVHD, and details the typical symptoms and presentations.

An expert on graft-vs-host disease provides an overview of GVHD prophylaxis and conditioning regimens prior to transplant.

Yi-Bin Chen, MD, an expert clinician and researcher, reviews a case study of a patient with GVHD and offers his initial impressions.

In an interview with Targeted Oncology, Lori Muffly, MD, discusses the subanalysis of a phase 1 study of briquilimab plus low-dose total body radiation and fludarabine which was presented at 2023 Tandem Meetings on Transplantation and Cellular Therapy.

In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the full data from the phase 2 trial of panobinostat, gemcitabine, busulfan, and melphalan for patients with high-risk, relapsed/refractory myeloma.

Samer A. Srour, MD, MS, discusses some of the takeaways from the dose-expansion phase of an ongoing phase 1 trial evaluating Orca-Q.